SGLT2 Inhibition: New Insight in Cardiology
Submission Deadline: 30 Sep 2022
Guest Editors
Robert J. Chilton DO, FACC, FACP, FACOI, FAHA
Division of Cardiology, Department of Medicine, University of Texas Health Science Centre at San Antonio, San Antonio, TX, USA
Interests: cardiovascular disease; hyperlipidemia; atherosclerosis; diabetes mellitus
Special Issue in IMR Press journals
Sinai Cardiology Faculty Group, LifeBridge Health, Baltimore, Maryland, USA
Interests: cardiovascular disease; cardio-renal medicine; hyperlipidemia
Special Issue Information
Dear Colleagues,
Diabetes is an established risk factor of cardiovascular disease and predictor of poor outcome. This explain why achieving adequate management of diabetes and hyperlipidemia, is a corner stone in most cardiology patients’ treatment plan. SGLT-2 inhibitors showed proven benefits on improving outcome in heart failure patients, both systolic and diastolic, even these who are not diabetic. As well, SGLT-2 inhibitors are recommended in diabetic patients with established cardiovascular disease for primary prevention. This emerging role of SGLT-2 inhibitors on multiple cardiac conditions, suggests this topic of SGLT-2 inhibitors: a new insight in cardiology.
Prof. Robert J. Chilton and Dr. Badr Harfouch
Guest Editors
Keywords
- heart failure
- coronary atherosclerosis
- diabetes mellitus
- SGLT-2 inhibitors
- lipo-toxicity
- metabolic inflexibility
- cardiomyocyte molecular function
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted manuscripts should be well formatted in good English.
Published Papers (5)
Sodium Glucose Co-Transporter Inhibition, an Expanding Impact
Rev. Cardiovasc. Med. 2023, 24(5), 130; https://doi.org/10.31083/j.rcm2405130
(This article belongs to the Special Issue SGLT2 Inhibition: New Insight in Cardiology)
Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
Rev. Cardiovasc. Med. 2023, 24(2), 36; https://doi.org/10.31083/j.rcm2402036
(This article belongs to the Special Issue SGLT2 Inhibition: New Insight in Cardiology)
SGLT2 Inhibition in Acute Myocardial Infarction—A Comprehensive Review
Rev. Cardiovasc. Med. 2023, 24(2), 32; https://doi.org/10.31083/j.rcm2402032
(This article belongs to the Special Issue SGLT2 Inhibition: New Insight in Cardiology)
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Rev. Cardiovasc. Med. 2023, 24(1), 1; https://doi.org/10.31083/j.rcm2401001
(This article belongs to the Special Issue SGLT2 Inhibition: New Insight in Cardiology)
Addressing Cardiovascular Disparities in Racial/Ethnic Populations: The Blood Pressure-Lowering Effects of SGLT2 Inhibitors
Rev. Cardiovasc. Med. 2022, 23(12), 411; https://doi.org/10.31083/j.rcm2312411
(This article belongs to the Special Issue SGLT2 Inhibition: New Insight in Cardiology)